Breast inflammation: Indications for MRI and PET-CT

Diagnostic and Interventional Imaging

Volumn 93, Issue 2, 2012, Pages 104-115

  De Bazelaire, C ^a   Groheux, D ^a   Chapellier, M ^a   Sabatier, F ^a   Scemama A ^a   Pluvinage, A ^a   Albiter, M ^a   De Kerviler, E ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Breast inflammation; MRI; PET

Indexed keywords

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST METASTASIS; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL PRACTICE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ECHOGRAPHY; HISTOPATHOLOGY; HUMAN; INFLAMMATORY BREAST CANCER; LYMPH NODE METASTASIS; MAMMOGRAPHY; MASTITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; FEMALE;

FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MASTITIS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY;

EID: 84863431200     PISSN: 22115684     EISSN: 22115684     Source Type: Journal    
DOI: 10.1016/j.diii.2011.12.004     Document Type: Article

References (36)

1. Froman J, Landercasper J, Ellis R, De Maiffe B, Theede L. Red breast as a presenting complaint at a breast center: An institutional review. Surgery 2011;149(6):813-9 [Epub 2011 Mar 11. Review].
2. Kamal RM, Hamed ST, Salem DS. Classification of inflammatory breast disorders and step by step diagnosis. Breast J 2009;15(4):367-80.
3. Sardanelli F, Boetes C, Borisch B, Decker T, Federico M, Gilbert FJ, et al. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer 2010;46(8):1296-316.
4. Renz DM, Baltzer PA, Bottcher J, Thaher F, Gajda M, Camara O, et al. Magnetic resonance imaging of inflammatory breast carcinoma and acute mastitis. A comparative study. Eur Radiol 2008;18(11):2370-80.
5. Rieber A, Zeitler H, Rosenthal H, Gorich J, Kreienberg R, Brambs HJ, et al. MRI of breast cancer: influence of chemotherapy on sensitivity. Br J Radiol 1997;70(833):452-8.
6. Jain RK, Tong RT, Munn LL. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 2007;67(6): 2729-35.
7. Belli P, Costantini M, Romani M, Pastore G. Role of magnetic resonance imaging in inflammatory carcinoma of the breast. Rays 2002;27(4):299-305.
8. Rieber A, Tomczak RJ, Mergo PJ, Wenzel V, Zeitler H, Brambs HJ. MRI of the breast in the differential diagnosis of mastitis versus inflammatory carcinoma and follow-up. J Comput Assist Tomogr 1997;21(1):128-32.
9. Malich A, Fischer DR, Wurdinger S, Boettcher J, Marx C, Facius M, et al. Potential MRI interpretation model: differentiation of benign from malignant breast masses. AJR Am J Roentgenol 2005;185(4):964-70.
10. Kuhl CK, Klaschik S, Mielcarek P, Gieseke J, Wardelmann E, Schild HH. Do T2-weighted pulse sequences help with the differential diagnosis of enhancing lesions in dynamic breast MRI? J Magn Reson Imaging 1999;9(2): 187-96.
11. Crowe DJ, Helvie MA, Wilson TE. Breast infection. Mammographic and sonographic findings with clinical correlation. Invest Radiol 1995;30(10):582-7.
12. Lee KW, Chung SY, Yang I, Kim HD, Shin SJ, Kim JE, et al. Inflammatory breast cancer: imaging findings. Clin Imaging 2005;29(1):22-5.
13. Morris EA, Schwartz LH, Drotman MB, Kim SJ, Tan LK, Liberman L, et al. Evaluation of pectoralis major muscle in patients with posterior breast tumors on breast MR images: early experience. Radiology 2000;214(1):67-72.
14. Yang WT, Le-Petross HT, Macapinlac H, Carkaci S, Gonzalez-Angulo AM, Dawood S, et al. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat 2008;109(3):417-26.
15. Bourguet P. Standards, options and recommendations for the use of PET-FDG in cancerology. Results in gynecological neoplasms. Bull Cancer 2003;90:S47-55 [special issue].
16. FNCLCC, et al. 2003 update of recommendations for clinical practice: standards, options and recommendations for the use of FDG-PET in the management of gynaecological and breast cancers. Gynecol Obstet Fertil 2004;32(4):352-71.
17. Groheux D, Giacchetti S, Moretti JL, Porcher R, Espié M, Lehmann-Che J, et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging 2011;38(3):426-35.
18. Carkaci S, Macapinlac HA, Cristofanilli M, Mawlawi O, Rohren E, Gonzalez, et al. Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data. J Nucl Med 2009;50(2):231-8.
19. Baslaim MM, Bakheet SM, Bakheet R, Ezzat A, El-Foudeh M, Tulbah A. 18-fluorodeoxyglucose-positron emission tomography in inflammatory breast cancer. World J Surg 2003;27(10):1099-104.
20. Dershaw DD, Moore MP, Liberman L, Deutch BM. Inflammatory breast carcinoma: mammographic findings. Radiology 1994;190(3):831-4.
21. Gunhan-Bilgen I, Ustun EE, Memis A. Inflammatory breast carcinoma: mammographic, ultrasonographic, clinical, and pathologic findings in 142 cases. Radiology 2002;223(3):829-38.
22. Alberini JL, Lerebours F, Wartski M, Fourme E, Le Stanc E, Gontier E, et al. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer. Cancer 2009;115(21):5038-47.
23. Groheux D, Hindié E, Rubello D, Espié M, Baillet G, Giacchetti S, et al. Should FDG PET/CT be used for the initial staging of breast cancer? Eur J Nucl Med Mol Imaging 2009;36(10):1539-42.
24. Korteweg MA, Zwanenburg JJ, van Diest PJ, van den Bosch MA, Luijten PR, van Hillegersberg R, et al. Characterization of ex vivo healthy human axillary lymph nodes with high resolution 7 Tesla MRI. Eur Radiol 2011;21(2):310-7.
25. Cooper KL, Harnan S, Meng Y, Ward SE, Fitzgerald P, Papaioannou D, et al. Positron emission tomography (PET) for assessment of axillary lymph node status in early breast cancer: a systematic review and meta-analysis. Eur J Surg Oncol 2011;37(3):187-98.
26. Lerebours F, Bieche I, Lidereau R. Update on inflammatory breast cancer. Breast Cancer Res 2005;7(2):52-8.
27. Groheux D, Giacchetti S, Espié M, Vercellino L, Hamy AS, Delord M, et al. The yield of 18FDG-PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study. J Nucl Med 2011;52(10):1526-34[Epub 2011 Aug 30].
28. Dose-Schwarz J, Tiling R, Avril-Sassen S, Mahner S, Lebeau A, Weber C, et al. Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer. Br J Cancer 2010;102(1):35-41.
29. Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L, et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol 2006;24(34):5366-72.
30. Groheux D, Giacchetti S, Espie M, Rubello D, Moretti JL, Hindie E. Early monitoring of response to neoadjuvant chemotherapy in breast cancer with 18F-FDG PET/CT: defining a clinical aim. Eur J Nucl Med Mol Imaging 2011;38(3):419-25.
31. Meisamy S, Bolan PJ, Baker EH, Bliss RL, Gulbahce E, Everson LI, et al. Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy-a pilot study at 4T. Radiology 2004;233(2):424-31.
32. Yankeelov TE, Lepage M, Chakravarthy A, Broome EE, Niermann KJ, Kelley MC, et al. Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging 2007;25(1): 1-13.
33. Sharma U, Danishad KK, Seenu V, Jagannathan NR. Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. NMR Biomed 2009;22(1):104-13.
34. Pickles MD, Gibbs P, Lowry M, Turnbull LW. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging 2006;24(7):843-7.
35. Manton DJ, Chaturvedi A, Hubbard A, Lind MJ, Lowry M, Maraveyas A, et al. Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy. Br J Cancer 2006;94(3):427-35.
36. Park SH, Moon WK, Cho N, Song IC, Chang JM, Park IA, et al. Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Radiology 2010;257(1):56-63.